United States · FDA National Drug Code directory
Inmazeb
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 61755-019_03d5650a-82d9-4af5-9515-ea52c93733ef
- Product NDC
- 61755-019
- Form
- INJECTION, SOLUTION
- Composition / generic term
- atoltivimab, maftivimab, and odesivimab-ebgn
- Labeler
- Regeneron Pharmaceuticals, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20210729
- Source listing expiry
- 20261231
Source-listed ingredients
- ATOLTIVIMAB — 483.3 mg/14.5mL
- MAFTIVIMAB — 483.3 mg/14.5mL
- ODESIVIMAB — 483.3 mg/14.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, SINGLE-DOSE in 1 CARTON (61755-019-01) / 14.5 mL in 1 VIAL, SINGLE-DOSE (61755-019-00) · 61755-019-01
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →